this little fucking worm and his cunt boss
wtf is this? Etesev-Bam?
Adverse Event Description
4/22/2021 Tested positive for COVID-19 discovered during Universal Testing on specific Unit. Resident was asymptomatic. COVID-19 screening completed every 4 hours. 4/26/2021Received therapeutic treatment Etesev-Bam 1400mg IV.5/2/2021 Developed increased temperature and foul smelling urine. Rocephin 1 Gram given daily on 5/2/2021 and 5/3/2021. 5/4/2021 declining clinical presentation with fatigue. Morphine and ativan started for End Of Line/Comfort Care. 5/10/2021 Continued declining vital signs, fatigue, pain. Deceased on 5/10/2021
Event Information
Patient Age 87.00 Sex Female
State / Territory Maine Date Report Completed 2021-07-29
Date Vaccinated 2021-01-13 Date Report Received 2021-07-29
Date of Onset 2021-04-22 Date Died 2021-05-10
Days to onset 99
Vaccine Administered By Senior Living * Vaccine Purchased By Not Applicable *
Mfr/Imm Project Number NONE Report Form Version 2
Recovered No Serious Yes
-
VAERS 2.0 Report Form Only
** VAERS-1 Report Form Only
"Not Applicable" will appear when information is not available on this report form version.
Event Categories
Death Yes
Life Threatening No
Permanent Disability No
Congenital Anomaly / Birth Defect * No
Hospitalized No
Days in Hospital None
Existing Hospitalization Prolonged No
Emergency Room / Office Visit ** N/A
Emergency Room * No
Office Visit * No
-
VAERS 2.0 Report Form Only
** VAERS-1 Report Form Only
"N/A" will appear when information is not available on this report form version.
Vaccine Type Vaccine Manufacturer Lot Dose Route Site
COVID19 VACCINE COVID19 (COVID19 (PFIZER-BIONTECH)) PFIZER\BIONTECH EL3302 2 IM
it's totally ok to give a big pharma therapeutic even if it's completelty experimental
https://www.covid19.lilly.com/bam-ete
Important facts about bamlanivimab and etesevimab
Bamlanivimab and etesevimab are investigational medicines used together in adults and adolescents (12 years of age or older who weigh at least 88 pounds [40 kg]) who are at high risk for developing severe COVID-19, including hospitalization or death for:
treatment of mild to moderate symptoms of COVID-19, OR
post-exposure prophylaxis for prevention of COVID-19 in persons who are:
not fully vaccinated against COVID-19 (individuals are considered to be fully vaccinated 2 weeks after their second dose in a 2-dose series [such as the Pfizer or Moderna vaccines], or 2 weeks after a single-dose vaccine [such as Johnson & Johnson’s Janssen vaccine]), or
are not expected to build up enough of an immune response to the complete COVID-19 vaccination (for example, someone with immunocompromising conditions, including someone who is taking immunosuppressive medications), and
have been exposed to someone who is infected with SARS-CoV-2. Close contact with someone who is infected with SARS-CoV-2 is defined as being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). For additional details, go here, or
someone who is at high risk of being exposed to someone who is infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons).
Bamlanivimab and etesevimab are not authorized for pre-exposure prophylaxis for prevention of COVID-19
Bamlanivimab and etesevimab have not been approved, but have been authorized for emergency use by the FDA. Bamlanivimab and etesevimab are authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab and etesevimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
Adverse Event Description
DIED FROM COVID-19; SUSPECTED CLINICAL VACCINATION FAILURE; This spontaneous report received from a company representative and a physician via social media concerned a 74 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included rheumatoid arthritis and patient was taking unspecified immune-suppressing medication.The patient received covid-19 vaccine ad26.cov2.s(suspension for injection, route of admin not reported, batch number: not reported) dose, start therapy date were not reported for an unspecified indication. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date the patient experienced Covid-19, and suspected clinical vaccination failure.The patient tested positive for Covid-19 four weeks after receiving the vaccine & later died from Covid-19. Her case was extremely rare. It was unknown if an autopsy was performed. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient died of Covid-19 on an unspecified date and the outcome of suspected clinical vaccination failure was not reported. This report was serious (Death, and Other Medically Important Condition).; Sender's Comments: V0: 20210644468-COVID-19 VACCINE AD26.COV2.S-DIED FROM COVID-19. This event is considered Unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. 20210644468-COVID-19 VACCINE AD26.COV2.S-SUSPECTED CLINICAL VACCINATION FAILURE. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: SPECIAL SITUATIONS.;Reported Cause(s) of Death: COVID-19